Provided by Tiger Fintech (Singapore) Pte. Ltd.

Veris Residential

16.47
+0.33002.04%
Post-market: 16.470.00000.00%16:40 EDT
Volume:418.16K
Turnover:6.86M
Market Cap:1.53B
PE:-66.03
High:16.48
Open:16.06
Low:16.06
Close:16.14
Loading ...

Acurx Pharmaceuticals, Inc. Announces Closing of $1.1 Million Registered Direct Offering

PR Newswire
·
11 Mar

Veris Residential Is Maintained at Hold by Truist Securities

Dow Jones
·
10 Mar

Truist Lifts Price Target on Veris Residential to $17 From $16, Keeps Hold Rating

MT Newswires Live
·
10 Mar

Veris Residential files to sell 522,020 shares of common stock for holders

TIPRANKS
·
04 Mar

Acurx Announces Publication of Nonclinical In Vivo Data Differentiating Ibezapolstat's Gut Microbiome Effects from Other Anti-CDI Antibiotics

CNW Group
·
03 Mar

Acurx Pharmaceuticals to Discuss Fourth Quarter and Full Year 2024 Financial Results on March 18, 2025 Conference Call and Provide Business Update

PR Newswire
·
28 Feb

Veris Residential Keeps Quarterly Dividend at $0.08 Per Share; Payable April 10 to Shareholders of Record on March 31

MT Newswires Live
·
28 Feb

Press Release: Veris Residential Declares Quarterly Cash Dividend

Dow Jones
·
28 Feb

Stock Track | Veris Residential Plunges 5.19% on Analyst Downgrade

Stock Track
·
26 Feb

Evercore ISI Downgrades Veris Residential to In Line From Outperform, Cuts Price Target to $18 From $20

MT Newswires Live
·
26 Feb

Veris Residential Cut to In-Line From Outperform by Evercore ISI Group

Dow Jones
·
26 Feb

Veris Residential downgraded to In Line from Outperform at Evercore ISI

TIPRANKS
·
26 Feb

Veris Residential (VRE) Receives a Buy from Evercore ISI

TIPRANKS
·
26 Feb

Veris Residential Q4 Core Adjusted FFO Decreases, Revenue Increases

MT Newswires Live
·
25 Feb

Veris Residential Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
25 Feb

Veris Residential (VRE) Q4 FFO and Revenues Miss Estimates

Zacks
·
25 Feb